Palmqvist, Sebastian http://orcid.org/0000-0002-9267-1930
Rossi, Marcello
Hall, Sara
Quadalti, Corinne
Mattsson-Carlgren, Niklas
Dellavalle, Sofia
Tideman, Pontus
Pereira, Joana B.
Nilsson, Maria H. http://orcid.org/0000-0002-6580-6721
Mammana, Angela
Janelidze, Shorena http://orcid.org/0000-0003-2869-8378
Baiardi, Simone http://orcid.org/0000-0002-7702-7856
Stomrud, Erik
Parchi, Piero http://orcid.org/0000-0002-9444-9524
Hansson, Oskar http://orcid.org/0000-0001-8467-7286
Article History
Received: 21 January 2023
Accepted: 8 June 2023
First Online: 18 July 2023
Competing interests
: None of the authors have any financial interest in the α-syn SAA test. S.P. has acquired research support (for the institution) from ki elements/Alzheimer Drug Discoveries Foundation. In the past 2 years he has received consultancy/speaker fees from Bioartic, Biogen, Eli Lilly and Roche. O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2 years he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Genentech, Novartis, Novo Nordisk, Roche and Siemens. The remaining authors declare no competing interests.